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The findings of the PACE trial1 seem impressive, but the discrepancy between the definitions 
of improvement in the protocol2 and paper requires an explanation. In the paper “clinically 
useful differences” were defined as 0·5 SD changes in fatigue or physical functioning 
compared with baseline. However, the criteria for improvement published in the trial protocol 
were much more demanding (see table2). Use of a cut-off score of 75 on the short-form 36 
physical functioning subscale, as originally proposed, would halve the number of “recovered” 
patients. Moreover, consulting the normative data for the scale reveals that the mean score of 
59 after both cognitive behaviour therapy and graded exercise improved a chronic fatigue 
syndrome patient’s physical functioning to the level of someone 40 years older than 
himself.3  Is this a case of “outcome reporting bias”?4 
 
Table 
 
Definition of positive outcome/improvement in the trial protocol and the final publication 
 
 
* Clinically useful difference of 2 points (0·5 SD) and mean baseline Likert score of 28·2. 
† Likert score of ≤18 used by the authors implies bimodal score of ≤4. 
‡ Clinically useful difference of 8 points (0·5 SD) and mean baseline short-form 36 (SF-36) physical 
function subscale score of 38·0. 
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